Mutations in DNMT3A are found in 22% of de novo AML cases7 where they sometimes are accompanied by mutations in either TET2 or IDH1/2, confirming the role of DNA methylation in normal hematopoiesis and leukemogenesis. Here, IDH1 is linked to acute myeloid leukemia.